Cubist Gets Entereg And A Late-Stage Compound With Adolor Buy
This article was originally published in The Pink Sheet Daily
The deal includes a contingent payment right tagged to Phase III-ready constipation drug ADL5945 that will provide extra consideration for Adolor shareholders if the drug reaches its upside potential.
You may also be interested in...
AstraZeneca’s peripherally acting mu-opioid receptor antagonist was not associated with an increased incidence of major cardiovascular events in Phase III studies of chronic pain patients with opioid-induced constipation. An FDA advisory committee will review CV safety data for the drug class June 11-12.
Cubist Pharmaceuticals will strengthen its position in the challenging antibiotic market with the acquisitions of two rivals, Optimer Pharmaceuticals and Trius Therapeutics. But it was Cubist’s current strength that allowed it to get those deals done on favorable, risk-sharing terms.
Cubist will rely on its experience in infectious disease to drive growth of Dificid for Clostridium difficile infection and to launch tedizolid for skin infections, but the commercial market for new antibiotics is daunting and re-creating the success of Cubicin won’t be easy.